Brad Hauser

Brad Hauser currently serves as President and Chief Executive Officer of Soliton within Allergan Aesthetics, an AbbVie company. Mr. Hauser served as President and CEO of Soliton, Inc. from November 2020 until it was acquired by Allergan Aesthetics in December 2021.  Previously, he served as  the Vice President, R&D and General Manager for CoolSculpting at Allergan Pharmaceuticals since ZELTIQ Aesthetics, Inc. was acquired in April 2017. Mr. Hauser served as the Senior Vice President of Research and Development at ZELTIQ Aesthetics, Inc. from January 2017 to April 2017 and as its Vice President of Research and Development from July 2015 to January 2017. Mr. Hauser joined ZELTIQ in December 2013 as Vice President of Product and Clinical Strategy. Prior to joining ZELTIQ, he held multiple roles in the aesthetic industry, including Executive Vice President of Commercial Operations for Cutera, Director of Research and Development at Medicis and Managing Director of Product and Clinical Marketing at Solta Medical. Mr. Hauser received his Bachelor of Arts in Human Biology from Stanford University.